NovoCure Ltd 8-K

What Happened
NovoCure announced top-line results from its Phase 3 TRIDENT trial on June 18, 2026 (Regulation FD disclosure). The trial compared initiating Tumor Treating Fields (TTFields) at the start of chemoradiation (Early Start Arm) versus initiating TTFields during the maintenance phase (Maintenance Start Arm) for newly diagnosed glioblastoma (GBM). In the intent-to-treat population, median overall survival was 17.7 months for the Early Start Arm versus 17.5 months for the Maintenance Start Arm (hazard ratio 0.953; p = 0.519), meaning the difference was not statistically significant. TTFields therapy was reported as well-tolerated with no new safety signals. The company said TRIDENT results have been accepted for presentation at ASTRO 2026.

Key Details

• Date filed: June 18, 2026 (8-K, Item 7.01 Regulation FD Disclosure).
• Primary endpoint (overall survival) not met: median OS 17.7 mo (Early Start) vs 17.5 mo (Maintenance); HR 0.953; p=0.519.
• Safety: TTFields, including initiation with chemoradiation, was well-tolerated; device-related safety consistent with prior GBM studies.
• Trial design: Phase 3, global, randomized, open-label, two-arm trial in newly diagnosed GBM; primary endpoint OS; multiple secondary endpoints (PFS, survival rates at 1–3 years, ORR per RANO, etc.).
• Results accepted for presentation at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting.

Why It Matters
A pivotal Phase 3 trial not meeting its primary endpoint is a material clinical result for NovoCure and for investors tracking TTFields in newly diagnosed GBM. These top-line data do not support a survival benefit from starting TTFields concurrently with chemoradiation versus starting during maintenance, though safety appears consistent with prior studies. Investors should watch for the detailed ASTRO presentation and any subsequent company commentary or subgroup analyses, which could provide more context on the results and next steps.